These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 30069630)

  • 1. Pomalidomide.
    Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
    Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide.
    Engelhardt M; Wäsch R; Reinhardt H; Kleber M
    Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
    Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
    Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
    Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
    Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
    Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
    Scott LJ
    Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib.
    Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
    Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
    Eleutherakis-Papaiakovou E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):921-928. PubMed ID: 31679403
    [No Abstract]   [Full Text] [Related]  

  • 16. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
    Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
    Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
    San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
    Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
    Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.